Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation
Which stocks are undervalued right now? Check free
Discover now →
Neurones S.A (0GX2) fair value: what the stock is really worth
As of Oct 2, 2026: fair value of Neurones S.A €63.38, price €35.70, upside +77.5%, quality 55 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
- Fair value above price? Yes
- Good quality? Yes
- Add to watchlist
NS
Some data
Sep 24, 2026
Neurones S.A
0GX2 · LSEClearly undervaluedStrong Fair Value upside, but quality is only moderate.
✓Fair value €63.38 · Strongly undervalued (+77.5%)
!Quality 55/100
✓Healthy Growth (revenue 5y +10.3 %/yr)
!Thin margins · 6.1% net margin (TTM)
✓Low debt · generates free cash flow
✓3.9% dividend yield · Sustainable
!Moderate moat 51/100
!Evidence only medium, so the estimate is less certain
What runs behind every stock
26
valuation models
8 families, DCF to NCAV
37
quality factors
margins, balance sheet, cashflow, debt
6
AI factors
moat, what no ratio measures
2,000+
data points
verified, per stock, median
69 individual criteria per stock, every one traceable See the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.
How to read this chart
60‑month range €13.21 – €47.39 · fair‑value band €45.50 – €89.22 · the €35.70 price screens below the €63.38 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 24, 2026.
Company profile
Neurones S.A. provides infrastructure, application, and consulting services in France. The company offers cloud, infrastructure management, DevOps, cybersecurity, user support, IT service management, information system governance, and automation services.
Show more
Neurones S.A. provides infrastructure, application, and consulting services in France. The company offers cloud, infrastructure management, DevOps, cybersecurity, user support, IT service management, information system governance, and automation services. It also provides digital, UX/UI, agile, devOps, mobility, and data; SAP integration and outsourcing content management, business process management, and paperless processes; IT consulting for the finance, big data, and AI and blockchain core businesses; and IT training and working with change. In addition, the company offers strategy consulting, management and digital transformation consulting, digital marketing consulting, and RH transformation consulting services. It serves banking/insurance, services/consumer goods, energy/utilities/healthcare, technology/media/telecoms, industry/construction and civil engineering, and public sector markets. Neurones S.A. was founded in 1984 and is headquartered in Nanterre, France.
Stock analysis
Neurones S.A (0GX2) currently trades at €35.70, while our model-based Fair Value estimate is €63.38, implying the stock looks roughly 43.7% undervalued today.
Show more
Valuation
Bull case: the DCF Models group reads highest at a median of €60.78 per share, and 18 of the 24 models we run sit above the €35.70 price.
Bear case: the Asset-Based group reads lowest at €11.05, and 6 of the 24 models stay below the price. Evidence for this calculation is medium.
Scenario range: €45.50 (bear) to €89.22 (bull), the price of €35.70 sits below it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 55/100 (solid quality), in the Technology sector.
Healthy Growth: Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Neurones S.A reported revenue of €857M in FY2025 versus €580M in FY2021, a compound +10.3%/yr. Reported net income was €61.9M in FY2025, compounding +13.2%/yr from FY2021.
Key figures
Market cap €1.0B · P/E ratio 0.2 · P/S ratio 0.02 · EPS (TTM) €1.55 · Dividend yield 3.9% · Net margin 7.2% · Return on equity 13.7% · Return on assets (EBIT) 10.7%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 53 out of 100 (low confidence).
What moves the price
The share trades about 17% below its 52-week high and 11% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Technology peers we cover trades at 44% fair-value upside, at 78%, 0GX2 screens cheaper than that median.
Fair Value models
Bear €45.50
Fair Value €63.38
Bull €89.22
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2025 figures (about 9 months old). Earnings retained since then (€0.1134 per share) are deliberately not added.
Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.
Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
FCF DCF
€43.69
€60.78
€85.58
81
Growth DCF
€43.48
€59.00
€80.41
79
Owner Earnings
€43.32
€60.20
€84.69
77
All 24 models by family
DCF Models
FCF DCF
€43.69
€60.78
€85.58
81
Owner Earnings
€43.32
€60.20
€84.69
77
5Y Revenue Exit
€41.55
€59.24
€82.47
73
5Y EBITDA Exit
€53.34
€82.62
€118.38
75
5Y P/E Exit
€55.18
€86.29
€120.77
70
10Y Revenue Exit
€41.27
€57.13
€79.85
67
10Y EBITDA Exit
€49.05
€72.45
€106.31
68
10Y P/E Exit
€50.16
€74.85
€108.07
64
Earnings-Based
Graham-Dodd
€17.36
€70.19
€95.50
64
Lynch FV
€17.53
€25.04
€32.56
61
PEG = 1.0
€17.53
€25.04
€32.56
57
EPV
€31.06
€33.38
€35.32
74
Multiples
P/E Multiple
€53.61
€71.48
€89.35
63
P/S Multiple
€32.55
€43.40
€54.25
58
P/B Multiple
€32.55
€43.40
€54.25
55
EV/EBIT
€67.74
€85.64
€103.54
66
EV/EBITDA
€64.33
€81.09
€97.85
67
EV/Revenue
€41.19
€52.82
€64.46
54
Asset-Based
NCAV (Graham)
€8.25
€11.05
€16.50
54
Growth DCF
Growth DCF
€43.48
€59.00
€80.41
79
Rev-Margin DCF
€41.55
€59.09
€80.81
73
Economic Profit
Residual Income
€15.74
€19.45
€28.08
75
ROIC Compounder
€31.82
€35.09
€38.36
72
Growth Earnings
Growth-Adj P/E
€36.56
€52.24
€67.91
67
Notify me when 0GX2 reaches fair value
Put 0GX2 on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.
Set up alert →Quality Score breakdown
Overall quality
55/100
Of which business quality 57 · Market factors (momentum, volatility) 43
Profitability
52
Margins and returns on capital today
Quality Growth
37
Are margins and returns improving?
Cashflow
56
Earnings quality: real cash, not paper profit
Fin. Strength
96
Balance sheet, leverage, solvency risk
Investment
78
Disciplined investing over empire-building
Low Volatility
80
Calm price path (market factor)
Momentum
31
Price trend over the last 3–12 months (market factor)
52W Momentum
20
Distance to the 52-week high (market factor)
Net Issuance
10
Share count: buybacks or dilution?
Revenue & earnings trend
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.
87/100
Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Revenue growth 1 year
+5.8%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+8.8%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+10.3%
Start year 2020 (pandemic). Over 10 years: +7.9% a year
Revenue growth 23 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+10.2%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate.
+14.9%
Earnings growth per share plus dividend.
Earnings per share, growth per year+11.0%
Dividend (yield on the price)3.9%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.11.0% vs 9.2%, steady
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.10% → 8%
Start year 2020 (pandemic)
Growth Forecast
Little optimism in the price
The price assumes less growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
−2.1%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (euro area: IMF forecast 2.2% a year to 2030, 2.6% from 2016 to 2025) that is about −4.2% a year for the price.
Watch 0GX2, get fair value alerts →
Compare Neurones S.A with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Context: sector, industry, market
- P/E, EV/EBITDA and margins by industry (reference tables)
- Undervalued stocks: UK Stocks
- Valuation of the UK market
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
None of the checked exposures detected
Similar stocks
10 more Information Technology Services stocks, each showing price versus our Fair Value estimate.
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| International Business Machines Corporation IBM | $219.93 | $186.56 | −15% |
| Accenture plc ACN | $183.37 | $305.06 | +66% |
| Tata Consultancy Services Limited TCS | ₹2,082 | ₹2,993 | +44% |
| Infosys Limited INFY | ₹994.10 | ₹1,691 | +70% |
| HCL Technologies Limited HCLTECH | ₹1,243 | ₹1,926 | +55% |
| Cognizant Technology Solutions Corporation CTSH | $56.84 | $138.62 | +144% |
| Amadeus IT Group AMS | €52.80 | €65.98 | +25% |
| Broadridge Financial Solutions, Inc BR | $161.15 | $159.88 | −1% |
| Fidelity National Information Services, Inc FIS | $33.35 | $32.72 | −2% |
| CDW Corporation CDW | $129.71 | $165.54 | +28% |
Explore undervalued stocks
More undervalued Technology stocks →
All undervalued stocks
TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks
Try a ready-made strategy
Pick a strategy and jump into the live analysis with that exact screen applied.
🥇 Backtested Best
🏆 Big Names
⭐ Top Rated
💎 Quality on Sale
🚀 Profitable Growth
🧊 Quality Compounders
💵 Dividend Stars
📈 Strong Momentum
📉 Fallen Angels
⚖️ Deeply Undervalued
🔍 Small-Cap Gems
🏰 Moat at a Fair Price
💼 Insider Buying
🎩 Buffett-Style Quality
📚 Peter Lynch GARP
🧮 Greenblatt Magic Formula
🛡️ Graham Defensive
Discover tools
Stock screenerFilter by region, size and sector
Compare toolTwo stocks side by side
Extrinsic Value Calculator…Calculator with industry benchmark
Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
Frequently asked questions
Is Neurones S.A (0GX2) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of €63.38 versus a price of €35.70, about +78% upside (undervalued).
What is the fair value of 0GX2?
Our model-based fair value for Neurones S.A is €63.38 (as of Sep 24, 2026), built from audited fundamentals. The current price: €35.70.
What is the quality score of 0GX2?
Neurones S.A has a Quality Score of 55/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Neurones S.A (0GX2)?
Our model-based price target is the fair value of €63.38 (as of Sep 24, 2026) from 24 valuation models. Cautious scenario €45.50, optimistic scenario €89.22. It is a calculation from audited fundamentals, not an analyst target.
What is the Neurones S.A stock forecast for 2026?
Our models put fair value at €63.38, about +78% upside versus a price of €35.70 (undervalued). Cautious scenario €45.50, optimistic scenario €89.22. The calculation is refreshed regularly with new filings.
What is the revenue of Neurones S.A (0GX2)?
Neurones S.A reported trailing-twelve-month revenue of about €857M (latest available figure, as of Sep 24, 2026).
Does Neurones S.A pay a dividend?
Neurones S.A currently shows a dividend yield of about 3.92% relative to its recent price (as of Sep 24, 2026).
What growth is priced into Neurones S.A (0GX2)?
For today's price to be fair in a discounted-cash-flow model, Neurones S.A would have to grow free cash flow by -2.1 % per year for five years (discount rate 10.3 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +10.3 % per year. As of Sep 24, 2026.
What discount rate (WACC) does the fair value of 0GX2 use?
Our models discount Neurones S.A at 10.3 %: a base by market capitalisation (small), damped by beta 0.42, country premium for United Kingdom. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Neurones S.A that is -2.1 % per year a year over ten years, using the same discount rate (10.3 %) and the same formula as our fair value.
How much growth has Neurones S.A (0GX2) delivered so far?
Over the past 5 years revenue at Neurones S.A grew +10.3 % a year. The price currently implies -2.1 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Neurones S.A (0GX2) growing?
The median revenue growth in the sector is +7.2 % a year. That is the yardstick for the growth priced into Neurones S.A (-2.1 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Neurones S.A (0GX2)?
The free-cash-flow yield on the price is 6.82 %: that much free cash flow Neurones S.A produces per unit of market value. When it exceeds the discount rate of our models (10.3 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Neurones S.A (0GX2)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Neurones S.A it is €63.38 per share (as of Sep 24, 2026), against a price of €35.70. It is the blended result of 24 valuation models (cash flow, earnings, asset, dividend).
Is Neurones S.A stock overvalued or undervalued in 2026?
As of Sep 24, 2026, 0GX2 trades below its calculated fair value: price €35.70, fair value €63.38, a gap of about +78% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 0GX2?
No. The price is what the market pays today (€35.70); the fair value is what the company's own numbers justify (€63.38). For Neurones S.A the two are €27.68 per share apart. That gap is exactly why we show both numbers side by side.
How much is Neurones S.A worth?
The market values Neurones S.A at about €1.0B (market capitalisation, as of Sep 24, 2026). Per share that is €35.70; our models calculate a fair value of €63.38 per share.
What do the bullish and bearish scenarios say about 0GX2?
Our models span a range for Neurones S.A: cautious scenario €45.50, base €63.38, optimistic €89.22 per share (as of Sep 24, 2026, price €35.70). The range comes from different growth and margin assumptions, not from analyst opinions.
How far is 0GX2 from its 52-week high?
Neurones S.A trades at €35.70, about 17% below its 52-week high of €43.20 and 11% above the low of €32.26 (as of Oct 2, 2026). Distance from the high says nothing about value: that is what the fair value of €63.38 is for.
Which stocks are comparable to Neurones S.A?
From the same area (Technology) we also value International Business Machines Corporation, Accenture plc, Tata Consultancy Services Limited, Infosys Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Neurones S.A stock attractive at the current price?
The data as of Sep 24, 2026: price €35.70, calculated fair value €63.38 (+78%), Quality Score 55/100, from 24 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 0GX2 calculated?
We run Neurones S.A through 24 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of €63.38, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5 % above its aggregate fair value. Neurones S.A currently trades 44 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Neurones S.A (0GX2)?
The closing price on Oct 2, 2026 was €35.70. Our model-based fair value is €63.38, about +78% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Neurones S.A right now?
The price is below even our cautious bear case (€45.50). The market is more pessimistic than our downside scenario. Solid quality (55/100) at a price below fair value, the discount is the argument here, not the business quality. A fairly wide model range (€45.50 to €89.22) leaves room in how you read the outcome.
Where does the earnings growth of Neurones S.A (0GX2) come from?
Earnings per share at Neurones S.A grew +9.6 % a year from 2014 to 2025. Broken into its drivers: revenue per share +7.3 %, EBIT margin +1.5 %, tax rate +1.5 %, residual (interest, one-offs) −0.8 %. The four rates multiply to the earnings growth rate, they do not add up. Start and end are three-year averages so a single exceptional year does not distort the result.
Key figures of Neurones S.A
How large is the market capitalisation of Neurones S.A (0GX2)?
The market capitalisation of Neurones S.A is €1.0B. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/E ratio of Neurones S.A (0GX2)?
The price-to-earnings ratio of Neurones S.A is 0.2 (as of Jul 24, 2026). Price to earnings: how many years of current profit you pay for the stock. A P/E of 10 means ten years of profit.
What is the P/S ratio of Neurones S.A (0GX2)?
The price-to-sales ratio of Neurones S.A is 0.02 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Neurones S.A (0GX2)?
Earnings per share at Neurones S.A are €1.55 (price ÷ EPS = P/E 0.2). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Neurones S.A (0GX2)?
The dividend yield of Neurones S.A is 3.9% (payout 90.3%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Neurones S.A (0GX2)?
The net margin of Neurones S.A is 7.2% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Neurones S.A (0GX2)?
The return on equity (ROE) of Neurones S.A is 13.7% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Neurones S.A (0GX2)?
On an EBIT basis the return on assets of Neurones S.A is 10.7% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Neurones S.A (0GX2)?
The operating margin of Neurones S.A is 9.8% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Neurones S.A (0GX2)?
Revenue at Neurones S.A is growing +6.1% versus a year earlier (3y avg +8.8%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Neurones S.A (0GX2)?
Earnings per share at Neurones S.A are growing +5.1% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net cash does Neurones S.A (0GX2) hold?
Neurones S.A holds more cash than debt, €304M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed
Continue in the live analysis
Fair value and trend for 35,000+ stocks, watchlist, comparison and the diversification check. You can also try 14 days of Pro there, no card.
Open the live analysis →Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.